Skip to content
Synopulse
  • The Brief
    • Quick
    • In Depth
    • Editor’s Pick
    • Findings
  • Reports
    • The beats
      • Catalyst
      • AccessWatch
      • DealPulse Signal
      • DealPulse Report
    • Analysis
      • The Throughline
      • The Top Line
      • The Forecast
    • Coverage
      • ShowFloor
      • The Arena
  • The Pulse
    • NeuroPulse
    • OrphanPulse
  • Topics
    • By subject
      • Deals
      • Regulatory
      • Market Access
      • Pricing & Reimbursement
      • Legal & Policy
    • By technology
      • Antibody
      • Cell & Gene Tx
      • Drug conjugates
      • AI/ML
      • Digital Health
      • Radiopharma
    • By therapy area
      • Neurology
      • Oncology
      • Rare Diseases
      • Cardio-Metabolic
      • Immunology & Inflammation
      • Orthopaedics

Moderna

The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers

August 20, 2026 by Athithi Verma
The First Phase 3 Win for an mRNA Cancer Therapy Arrives Without Its Numbers

The first Phase 3 win for an mRNA cancer therapy. Statistical significance was reported, effect size was not, and overall survival is still open.

Categories Clinical Read, Oncology, Quick, RNA, The Brief Tags Global, Immuno-oncology, Intismeran autogene, KEYTRUDA, Melanoma, Merck & Co, Moderna, Neoantigen Therapy, Phase 3
Synopulse Weekly Pulse: Access Decisions, Regulatory Events & Market Dynamics, Week of Nov 24 2025

Synopulse Weekly Pulse – November 24, 2025

Read Now
  • Access Read
  • AI/ML
  • Analysis
  • Antibody
  • Approval
  • Cardio-Metabolic
  • Cell & Gene Tx
  • CI read
  • Clinical Read
  • Coverage
  • Deal Read
  • DealPulse
  • DealPulse Report
  • DealPulse Signal
  • Deals
  • Diagnostics
  • Digital Health
  • Drug conjugates
  • Drug Repurposing
  • Editor's Pick
  • Findings
  • Immunology & Inflammation
  • In Depth
  • Launch
  • Legal & Policy
  • Market Access
  • MedTech
  • Neurology
  • NeuroPulse
  • News
  • Oncology
  • Ophthalmology
  • OrphanPulse
  • Orthopaedics
  • Peptide
  • Pricing & Reimbursement
  • Pulmonology
  • Quick
  • Radiopharma
  • Rare Diseases
  • Regulatory
  • Reports
  • RNA
  • Science Read
  • ShowFloor
  • Small Molecule
  • The beats
  • The Brief
  • The Pulse
  • The Throughline
  • August 2026
  • July 2026
  • June 2026
  • May 2026
  • March 2026
  • January 2026
  • December 2025
  • November 2025
  • October 2025
  • September 2025
  • July 2025
  • June 2025
  • February 2025
  • January 2025
  • October 2024
  • September 2024
Synopulse
Contact Us

Explore Synopulse

  • NeuroPulse
  • Deals
  • Market Access
  • Industry Trends
  • Regulatory

About

  • About Synopulse
  • Contact Us
  • Announcements
© 2026 Synopulse • Built with GeneratePress